-- Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients

-- Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

-- Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021

Roxana Drake, MD, PhD from Novartis will give a presentation on January 29, 2016 from 09:00 to 10:00 EST (15:00-16:00 CET) entitled Clofazimine – repurpose & strategy.

Novartis recognized for licensing agreement to provide promising drug candidates to the Global Alliance for TB Drug Development

Award recognizes ‘game changing’ innovations that have the potential to solve long-standing challenges in medicine, nutrition, sanitation, energy and living standards

Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.